Pharsight

Coreg Cr generic

Coreg Cr is an anti-hypertensive drug owned by Woodward. The active ingredient in Coreg Cr is carvedilol phosphate. It was first authorized for market use on October 20, 2006. The drug has a total of 4 patents, 2 of which have already expired.

When will Coreg Cr generic be available?

The generic version of Coreg Cr is expected to be released after March 11, 2026, following the expiry of the last patent, US8101209*PED, on this date. It's worth mentioning that this does not guarantee the immediate availability of the generic drug, as it may depend on other factors such as the submission of a Para IV certification by other drug manufacturers.

Coreg Cr uses

Coreg Cr is primarily used for the treatment of hypertension and congestive heart failure. The drug works through its active ingredient, carvedilol phosphate, which helps to lower the pressure and stress on the heart, thereby improving its efficiency.

Coreg Cr patent expiration

Coreg Cr is protected by 4 patents, out of which 2 have expired. The remaining patents, US8101209 and US8101209*PED, are scheduled to expire on September 11, 2025 and March 11, 2026 respectively. After the expiry of the final patent, the generic of Coreg CR may become available. Below are the details of the patents:

Coreg Cr dosage

Want to ask something?